Oncopeptides is a global biopharmaceutical company focused on the development of therapies for difficult-to-treat hematological cancers. Every day we are inspired by the perseverance that we see from patients, care givers and health care providers in their fight against cancer. We are unwavering in our focus and dedication to bring hope to patients through new and meaningful treatment options. In 2000, Oncopeptides was founded by leading Swedish scientists. Since that time, Oncopeptides has developed a proprietary Peptide-Drug Conjugate (PDC) Platform. In June 2020, Oncopeptides submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of our lead product candidate, melphalan flufenamide (also referred to as melflufen). The Prescription Drug User Fee Act (PDUFA) has been set for February 28, 2021. Melphalan flufenamide is an anti-cancer PDC that rapidly delivers an alkylator payload into tumor cells and it is under review for patients with triple-class refractory multiple myeloma.
Oncopeptides is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. The company is in a strong financial position and has an effective Executive Team and Board of Directors. Discover more about Oncopeptides at www.oncopeptides.com